Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maud Charpentier

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Molecular Oncology|August 21, 2021
hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cellsMaud Charpentier, Emilie Dupré, Agnès Fortun, et al.
Oncoimmunology|March 26, 2019
Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cellsCatherine Rabu, Laurie Rangan, Laetitia Florenceau, et al.
The Journal of Clinical Investigation|January 21, 2021
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor controlClaire Lhuillier, Nils-Petter Rudqvist, Takahiro Yamazaki, et al.
Nature Communications|August 24, 2023
Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumorsNils-Petter Rudqvist, Maud Charpentier, Claire Lhuillier, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Molecular Oncology|August 21, 2021
hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cellsMaud Charpentier, Emilie Dupré, Agnès Fortun, et al.
Oncoimmunology|March 26, 2019
Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cellsCatherine Rabu, Laurie Rangan, Laetitia Florenceau, et al.
The Journal of Clinical Investigation|January 21, 2021
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor controlClaire Lhuillier, Nils-Petter Rudqvist, Takahiro Yamazaki, et al.
Nature Communications|August 24, 2023
Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumorsNils-Petter Rudqvist, Maud Charpentier, Claire Lhuillier, et al.
Pageof 2